+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Markets for Vaccine Technologies 2021-2026

  • ID: 5139318
  • Report
  • November 2021
  • Region: Global
  • 188 Pages
  • BCC Research

The global market for vaccine technologies should grow from $38.2 billion in 2021 to $55.1 billion by 2026 with a compound annual growth rate (CAGR) of 7.6% for the period of 2021-2026. 




Subunit, recombinant, polysaccharide, and conjugate vaccine technology market should grow from $19.9 billion in 2021 to $29.0 billion by 2026 with a compound annual growth rate (CAGR) of 7.8% for the period of 2021-2026. 


The live-attenuated vaccine technology market should grow from $7.1 billion in 2021 to $10.2 billion by 2026 with a compound annual growth rate (CAGR) of 7.4% for the period of 2021-2026.


Report Scope

This report explains critical trends in the vaccine industry. It discusses the market determinants, which act as motivating or restraining factors and provides insights to stakeholders and potential entrants.


This report includes only human vaccines; animal vaccines haven’t been considered in this report.


This study looks at research and development (R&D) spending, increasing competition and new technologies, which are giving direction to the market. These advancements, new product launches and changing lifestyles are influencing the future market growth.


Company merger acquisition strategies and collaborations are also covered in this report. Additionally, this study discusses the strengths and weaknesses of each strategy type, considering new technologies, growing competition, and changing customer needs.


The market has been analyzed based on the application of current vaccines. Categories considered in this report include pneumococcal vaccines; diphtheria, tetanus vaccines; HPV vaccines, MMR vaccines and other vaccines including rotavirus vaccines, influenza vaccines, hepatitis B vaccines, chickenpox vaccines, polio vaccines, BCG, and yellow fever vaccines.


This study details market growth among vaccine manufacturers and end-users. Genomic research centers, academic institutions, government and private laboratories and various hospital settings. Pharmaceutical, diagnostic and biotechnology companies and physicians will find this study to be of interest.


This report provides useful information to all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this study useful.


The Report Includes

  • 32 data tables and 54 additional tables
  • An updated review of the global market for vaccine technologies within the biopharmaceutical industry
  • Analyses of the global market trends, with data from 2019-2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
  • Evaluation and forecast the overall vaccine technologies market size (in USD millions), and corresponding market share analysis by technology, disease indication, age and geographic region
  • Identification of present and future strategies within the vaccine technology market and examination of vaccines for both humans and animals
  • Highlights of market opportunities for this innovation-driven vaccine technologies market, and the major regions and countries involved in market developments and their immunization schedule
  • Discussion of government regulations and policies, patent analyses and upcoming technologies, R&D activities related to the vaccine technology industry
  • Emphasis on COVID-19 pandemic impact on the present and future vaccines market, major COVID-19 vaccine candidates under development, and impact of the outbreak on vaccine supplies
  • Profile descriptions of the leading vaccine manufacturers/suppliers, including Abbott Laboratories, Bharat Biotech International Ltd., GlaxoSmithKline Plc, Merck & Co. Inc, Sanofi Pasteur SA, and Panacea Biotec Ltd.
Frequently Asked Questions about the Global Market for Vaccine Technologies

What is the estimated value of the Global Market for Vaccine Technologies?

The Global Market for Vaccine Technologies was estimated to be valued at $38.2 Billion in 2021.

What is the growth rate of the Global Market for Vaccine Technologies?

The growth rate of the Global Market for Vaccine Technologies is 7.6%, with an estimated value of $55.1 Billion by 2026.

What is the forecasted size of the Global Market for Vaccine Technologies?

The Global Market for Vaccine Technologies is estimated to be worth $55.1 Billion by 2026.

Who are the key companies in the Global Market for Vaccine Technologies?

Key companies in the Global Market for Vaccine Technologies include Abbott Laboratories, AstraZeneca, Bavarian Nordic A/S, Bharat Biotech International Ltd., Emergent Biosolutions Inc., GlaxoSmithKline Plc, Johnson & Johnson Inc., Merck & Co. Inc and Panacea Biotec Ltd..

Table of Contents

Chapter 1 Introduction
  • Study Background
  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • What's New in this Update
  • COVID-19 Update
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports


Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
  • Definitions
  • Immune System and Vaccines
  • How Vaccines Work
  • Types of Immunity
  • Advantages of Vaccination
  • History of Vaccines
  • Vaccines and Immunization, Overview
  • Types of Vaccines
  • Attenuated (Live) Vaccines
  • Inactivated (Killed) Vaccines
  • Toxoid Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • Recombinant Vector Vaccines
  • DNA Vaccines
  • RNA Vaccines
  • Immunization
  • Advantages of Immunization
  • Adjuvants and Excipients
  • Pathogen Components
  • Particulate Adjuvants
  • Infectious Diseases Preventable by Vaccine
  • Human Diseases
  • Viral Diseases
  • Bacterial Diseases
  • Regulatory Aspects
  • World Health Organization (WHO) Prequalified Vaccines
  • New Product Approvals
  • Recalls
  • Vaccine Shortage
  • Significant Regulatory Developments in Vaccines


Chapter 4 Global Market for COVID-19 Vaccines
  • Overview
  • COVID-19 Vaccine Technologies
  • Advent of mRNA Technology
  • Impact of COVID-19 on Routine Infant Vaccination
  • COVID-19 Disruptions
  • Stagnating Global Coverage Rate
  • Progress and Challenges by Country and Region


Chapter 5 Market Dynamics
  • Market Drivers
  • Growing Awareness of Immunization
  • Growing Investments and R&D
  • New Vaccines
  • Prevalence of Infectious Diseases
  • Market Restraints
  • Vaccine Development and Pricing
  • Market Opportunities
  • Increased Demand from Emerging Markets
  • Therapeutic Vaccines
  • Competitive Landscape
  • Company Share Analysis


Chapter 6 Market Breakdown by Technology
  • Global Market for Vaccine Technologies by Vaccine Type
  • Subunit, Recombinant, Polysaccharide and Conjugate Vaccines
  • Live-Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines
  • Other/Combination Vaccines


Chapter 7 Market Breakdown by Disease
  • Global Market for Vaccine Technologies by Disease
  • Pneumococcal
  • Diphtheria and Tetanus
  • HPV
  • MMR
  • Others


Chapter 8 Market Breakdown by Age Group Treated
  • Global Market for Vaccine Technologies by Age Group Treated
  • Pediatrics
  • Adolescents and Adults


Chapter 9 Market Breakdown by Region
  • Global Market for Vaccine Technologies by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of World


Chapter 10 Company Profiles
  • Abbott Laboratories
  • AstraZeneca
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Emergent Biosolutions Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Inc.
  • Merck & Co. Inc
  • Mitsubishi Tanabe Pharma Corp.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur Sa


Chapter 11 Appendix: List of Acronyms
List of Tables
Table A: Changes in the Segmentation of the Old and Updated Versions of This Report
Summary Table A: Global Market for Vaccine Technologies, by Vaccine Type, Through 2026
Summary Table B: Global Market for COVID-19 Vaccines, Through 2026
Table 1: History of Vaccines
Table 2: Types of Attenuated (Live) Vaccines
Table 3: Pros and Cons of Attenuated (Live) Vaccines
Table 4: Types of Inactivated (Killed) Vaccines
Table 5: Pros and Cons of Inactivated (Killed) Vaccines
Table 6: Types of Toxoid Vaccines
Table 7: Pros and Cons of Toxoid Vaccines
Table 8: Types of Subunit Vaccines
Table 9: Pros and Cons of Subunit Vaccines
Table 10: Types of Conjugate Vaccines
Table 11: Pros and Cons of Conjugate Vaccines
Table 12: Types of Recombinant Vector Vaccines, by Segment
Table 13: Pros and Cons of Recombinant Vector Vaccines
Table 14: Types of DNA Vaccines, by Segment
Table 15: Pros and Cons of DNA Vaccines
Table 16: Pros and Cons of RNA Vaccines
Table 17: Vaccine Excipient and Media Summary, Excipients included in U.S. Vaccines
Table 18: Vaccine-Preventable Human Viral Diseases
Table 19: Vaccine-Preventable Human Bacterial Diseases
Table 20: WHO Prequalified Vaccines, Jan. 2014–April 2020
Table 21: Newly Approved Vaccines, Jan. 2014–April 2020
Table 22: Global Vaccine Recalls, by Manufacturer, Jan. 2014-Nov. 2017
Table 23: Global Vaccine Shortage, by Manufacturer, Jan. 2012–Nov. 2017
Table 24: Global Market for COVID-19 Vaccines, Through 2026
Table 25: WHO Approved COVID-19 Vaccines: Companies and Technology Adopted
Table 26: COVID-19 Vaccines in the Pipeline
Table 27: Emerging Viral Infectious Diseases, 1900-2020
Table 28: Global Market for Vaccine Technologies, by Vaccine Type, Through 2026
Table 29: Global Market for Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, by Region, Through 2026
Table 30: Global Market for Live-Attenuated Vaccines, by Region, Through 2026
Table 31: Global Market for Inactivated Vaccines, by Region, Through 2026
Table 32: Global Market for Toxoid Vaccines, by Region, Through 2026
Table 33: Global Market for Other/Combination Vaccines, by Region, Through 2026
Table 34: Vaccines, by Disease Type
Table 35: Global Market for Vaccine Technologies, by Disease, Through 2026
Table 36: Global Market for Vaccine Technologies for Pneumococcal Disease, by Region, Through 2026
Table 37: Global Market for Vaccine Technologies for Diphtheria and Tetanus, by Region, Through 2026
Table 38: Global Market for Vaccine Technologies for HPV, by Region, Through 2026
Table 39: Global Market for Vaccine Technologies for MMR, by Region, Through 2026
Table 40: Seasonal Influenza Vaccines
Table 41: Global Market for Vaccine Technologies for Other Diseases, by Region, Through 2026
Table 42: Global Market for Vaccine Technologies, by Age Group Treated, Through 2026
Table 43: Pediatric Vaccine Doses
Table 44: Pediatric/VFC Vaccine Price List, 2019
Table 45: Influenza Vaccine Price List, 2020
Table 46: Global Market for Vaccine Technologies for Pediatrics, by Region, Through 2026
Table 47: Price List of Vaccines for Adults
Table 48: Global Market for Vaccines for Adolescents and Adults, by Region, Through 2026
Table 49: Global Market for Vaccine Technologies, by Region, Through 2026
Table 50: North American Market for Vaccine Technologies, by Vaccine Type, Through 2026
Table 51: North American Market for Vaccine Technologies, by Country, Through 2026
Table 52: Immunization Schedule, Canada, 2020
Table 53: European Market for Vaccine Technologies, by Vaccine Type, Through 2026
Table 54: European Market for Vaccine Technologies, by Country, Through 2026
Table 55: Immunization Schedule, Germany, 2020
Table 56: Immunization Schedule, France, 2020
Table 57: Vaccination and Immunization Schedule, U.K., 2020
Table 58: Immunization Schedule, Italy, 2020
Table 59: Asia-Pacific Market for Vaccine Technologies, by Vaccine Type, Through 2026
Table 60: Asia-Pacific Market for Vaccine Technologies, by Country, Through 2026
Table 61: Immunization Schedule, China, 2020
Table 62: Immunization Schedule, Japan, 2020
Table 63: Immunization Schedule, India, 2020
Table 64: GAVI Support to India, 2001-2021
Table 65: Vaccination Coverage Estimate, the Middle East and North Africa, 2014-2020
Table 66: Vaccination Coverage, Latin America, and the Caribbean, 2014-2020
Table 67: Rest of World Market for Vaccine Technologies, by Vaccine Type, Through 2026
Table 68: AstraZeneca: Vaccines
Table 69: AstraZeneca: Recent Developments, 2021
Table 70: Bavarian Nordic A/S: Recent Developments, 2021
Table 71: Bharat Biotech: Vaccines
Table 72: Bharat Biotech: Recent Developments, 2021
Table 73: Emergent BioSolutions Inc: Vaccines
Table 74: Emergent BioSolutions Inc: Recent Developments, 2021
Table 75: GlaxoSmithKline Plc: Vaccines Offered
Table 76: GlaxoSmithKline Plc.: Recent Developments, 2021
Table 77: Johnson & Johnson Inc.: Recent Developments, 2021
Table 78: Merck & Co. Inc.: Vaccines
Table 79: Merck & Co. Inc.: Recent Developments, 2021
Table 80: Pfizer Inc.: Recent Developments 2021
Table 81: Sanofi Pasteur SA: Vaccines
Table 82: Sanofi Pasteur SA: Recent Developments, 2021
Table 83: Acronyms Used in This Report


List of Figures
Summary Figure A: Global Market for Vaccine Technologies, by Vaccine Type, 2019-2026
Summary Figure B: Global Market for COVID-19 Vaccines, 2019-2026
Figure 1: Global Market Share of COVID-19 Vaccines, by Technology, 2021
Figure 2: Global Market Share for Vaccine Technologies, by Company, 2020
Figure 3: Global Market Share for Vaccine Technologies, by Technology, 2020
Figure 4: Global Market for Subunit, Recombinant, Polysaccha
Figure 5: Global Market for Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, by Region, 2019-2026
Figure 6: Global Market for Live-Attenuated Vaccines, 2019-2026
Figure 7: Global Market for Live-Attenuated Vaccines, by Region, 2019-2026
Figure 8: Global Market for Inactivated Vaccines, 2019-2026
Figure 9: Global Market for Inactivated Vaccines, by Region, 2019-2026
Figure 10: Global Market for Toxoid Vaccines, 2019-2026
Figure 11: Global Market for Toxoid Vaccines, by Region, 2019-2026
Figure 12: Global Market for Other/Combination Vaccines, 2019-2026
Figure 13: Global Market for Other/Combination Vaccines, by Region, 2019-2026
Figure 14: Global Market Share of Vaccine Technologies, by Disease, 2020
Figure 15: Global Market for Vaccine Technologies for Pneumococcal Disease, 2019-2026
Figure 16: Global Market for Vaccine Technologies for Pneumococcal Disease, by Region, 2019-2026
Figure 17: Global Market for Vaccine Technologies for Diphtheria and Tetanus, 2019-2026
Figure 18: Global Market for Vaccine Technologies for Diphtheria and Tetanus, by Region, 2019-2026
Figure 19: Global Market for Vaccine Technologies for HPV, 2019-2026
Figure 20: Global Market for Vaccine Technologies for HPV, by Region, 2019-2026
Figure 21: Global Market for Vaccine Technologies for MMR, 2019-2026
Figure 22: Global Market for Vaccine Technologies for MMR, by Region, 2019-2026
Figure 23: Global Market for Vaccine Technologies for Other Diseases, 2019-2026
Figure 24: Global Market for Vaccine Technologies for Other Diseases, by Region, 2019-2026
Figure 25: Global Market Share of Vaccine Technologies, by Age Group Treated, 2020
Figure 26: Global Market for Vaccine Technologies for Pediatrics, 2019-2026
Figure 27: Global Market for Vaccine Technologies for Pediatrics, by Region, 2019-2026
Figure 28: Global Market for Vaccines for Adolescents and Adults, 2019-2026
Figure 29: Global Market for Vaccines for Adolescents and Adults, by Region, 2019-2026
Figure 30: Global Market for Vaccine Technologies, by Region, 2019-2026
Figure 31: Global Market Share of Vaccine Technologies, by Region, 2020
Figure 32: North American Market Share for Vaccine Technologies, by Vaccine Type, 2020
Figure 33: North American Market Share for Vaccine Technologies, by Country, 2020
Figure 34: U.S. Market for Vaccine Technologies, 2019-2026
Figure 35: Canadian Market for Vaccine Technologies, 2020-2026
Figure 36: European Market Share for Vaccine Technologies, by Vaccine Type, 2020
Figure 37: European Market Share for Vaccine Technologies, by Country, 2020
Figure 38: German Market for Vaccine Technologies, 2019-2026
Figure 39: Russian Market for Vaccine Technologies, 2019-2026
Figure 40: French Market for Vaccine Technologies, 2019-2026
Figure 41: U.K. Market for Vaccine Technologies, 2019-2026
Figure 42: Italian Market for Vaccine Technologies, 2019-2026
Figure 43: Spanish Market for Vaccine Technologies, 2019-2026
Figure 44: Rest of European Market for Vaccine Technologies, 2019-2026
Figure 45: Asia-Pacific Market Share for Vaccine Technologies, by Vaccine Type, 2020
Figure 46: Asia-Pacific Market Share for Vaccine Technologies, by Country, 2020
Figure 47: Chinese Market for Vaccine Technologies, 2019-2026
Figure 48: Japanese Market for Vaccine Technologies, 2019-2026
Figure 49: Australian Market for Vaccine Technologies, 2019-2026
Figure 50: Indian Market for Vaccine Technologies, 2019-2026
Figure 51: Korean Market for Vaccine Technologies, 2019-2026
Figure 52: Rest of Asia-Pacific Market for Vaccine Technologies, 2019-2026
Figure 53: Rest of World Market Share for Vaccine Technologies, by Technology, 2020
Figure 54: Abbott Laboratories: Net Revenue, 2016-2020
Figure 55: Abbott Laboratories: Revenue Share, by Business Segment, 2020
Figure 56: Abbott Laboratories: Revenue Share, by Region, 2020
Figure 57: AstraZeneca: Net Revenue, 2016-2020
Figure 58: AstraZeneca: Revenue Share, by Business Segment, 2020
Figure 59: AstraZeneca: Revenue Share, by Region, 2020
Figure 60: Bavarian Nordic A/S: Net Revenue, 2016-2020
Figure 61: Bavarian Nordic A/S: Revenue Share, by Region, 2020
Figure 62: Emergent BioSolutions Inc: Net Revenue, 2016-2020
Figure 63: GlaxoSmithKline Plc: Net Revenue, 2016-2020
Figure 64: GlaxoSmithKline Plc: Revenue Share, by Business Segment, 2020
Figure 65: GlaxoSmithKline Plc: Revenue Share, by Region, 2020
Figure 66: Johnson & Johnson Inc.: Net Revenue, 2016-2020
Figure 67: Johnson & Johnson Inc.: Revenue Share, by Business Segment, 2020
Figure 68: Johnson & Johnson Inc.: Revenue Share, by Region, 2020
Figure 69: Merck & Co. Inc.: Net Revenue, 2016-2020
Figure 70: Merck & Co. Inc.: Revenue Share, by Business Segment, 2020
Figure 71: Merck & Co. Inc.: Revenue Share, by Region, 2021
Figure 72: Mitsubishi Tanabe Pharma Corp.: Net Revenue, 2016-2020
Figure 73: Mitsubishi Tanabe Pharma Corp.: Revenue Share, by Business Segment, 2020
Figure 74: Mitsubishi Tanabe Pharma Corp.: Revenue Share, by Region, 2020
Figure 75: Panacea Biotec LTD.: Net Revenue, 2016-2020
Figure 76: Panacea Biotec LTD: Revenue Share, by Business Segment, 2020
Figure 77: Panacea Biotec LTD: Revenue Share, by Region, 2020
Figure 78: Pfizer Inc.: Net Revenue, 2017-2021
Figure 79: Pfizer Inc.: Revenue Share, by Region, 2021
Figure 80: Sanofi Pasteur SA: Net Revenue, 2017-2021
Figure 81: Sanofi Pasteur SA: Revenue Share, by Business Segment, 2020
Figure 82: Sanofi Pasteur SA: Revenue Share, by Region, 2021

Samples

Loading
LOADING...

Executive Summary

Growth in the vaccine market is anticipated on the basis of technological advancements. Advancements will occur in regard to the development of novel vaccines for emerging infectious diseases, cancers, and allergies. Continuous improvements in vaccine design, delivery technologies and manufacturing will also boost the market growth.


The global vaccine technologies market is segmented in this report by technology, disease, age, and region.


Reasons for Doing This Study:

Vaccines are widely-used preventive pharmaceutical products that are increasingly adopted, worldwide. Globally, the menace of infectious and non-infectious diseases creates demand for different types of vaccines. Vaccination is one of the most cost-effective ways to reduce the global disease load. The overall increase in infectious and non-infectious diseases, growing population, technological advancements and continuous innovations create considerable scope for the vaccine technologies market. The resurgence of vaccine-preventable diseases and the emergence of new pandemics and immunization programs in emerging economies influence the global vaccine market.


This report is designed to be a critical decision-making tool for the intended audience, which includes vaccine market players, potential market entrants and other professionals involved with or interested in immunology and vaccine-preventable diseases.


Companies Mentioned

  • Abbott Laboratories
  • AstraZeneca
  • Bavarian Nordic A/S
  • Bharat Biotech International Ltd.
  • Emergent Biosolutions Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Inc.
  • Merck & Co. Inc
  • Mitsubishi Tanabe Pharma Corp.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi Pasteur Sa